[Comment] 3 months of romosozumab: a pragmatic clinical solution

A longstanding goal in the treatment of osteoporosis has been rejuvenating the ageing skeleton to essentially reverse or cure osteoporosis. Although antiresorptive drugs such as bisphosphonates or denosumab are effective at inhibiting bone resorption, their effects on increasing bone mass are modest and do not involve new bone formation.1 The advent of drugs capable of stimulating new bone formation—teriparatide, abaloparatide, and romosozumab—garnered initial enthusiasm that these drugs could help achieve cures for osteoporosis.